Message Font: Serif | Sans-Serif
No. of Recommendations: 1
Incyte used some of its cash to buy into a promising HIV candidate. Here are the results from a phase I trial for the drug:

Incyte has obtained rights in the major markets (U.S., Europe and Japan), leaving Pharmasset with the rest of the world. The drug, like most HIV drugs, appears to be on the fast track.

Nice 25% jump on the news today.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.